Anemia management and treatment response in patients on hemodialysis: The MAR study

Journal of Nephrology

Volumn 19, Issue 3, 2006, Pages 352-360

  Portolés, Jose ^a   Lopez Gomez, J M ^b   Aljama, P ^c  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; FERROUS GLUCONATE; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; ANTIANEMIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; HEART FAILURE; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; RISK FACTOR; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RENAL REPLACEMENT THERAPY; SPAIN;

AGED; ANEMIA; COHORT STUDIES; CROSS-SECTIONAL STUDIES; EPOETIN ALFA; FEMALE; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; SPAIN;

EID: 33749077759     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of CV disease in CRD. J Am Soc Nephrol 1998; 9 (Suppl 12): S16-23.
2. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ. Traditional CVD risk factors in dialysis patients compared with general population: the CHOICE study. J Am Soc Nephrol 2002; 13: 1918-27.
3. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in HD patients. J Am Soc Nephrol 1999; 10: 610-9.
4. Ofsthun N, Labrecque J, Lacson E, Keen M. The effects of higher hemoglobin levels on mortality and hospitalization in HD patients. Kidney Int 2003; 63: 1908-14.
5. Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in HD patients. J Am Soc Nephrol 1999; 10: 1309-16.
6. Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, Greenwood R, Feldman HI, Port FK, Held PJ. Anemia in HD patients of five european countries: association with morbidity and mortality in DOPPS. Nephrol Dial Transplant 2004; 19: 121-32.
7. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular disease. Am J Kidney Dis 1998; 32: 853-905.
8. European Best Practice Guidelines on anemia management. Nephrol Dial Transplant 1999; 14 (Suppl 4): 1-50.
9. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
10. Beddhu S, Bruns FJ, Saul M, Seddon P, Zeidel ML. A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med 2000; 108: 609-13.
11. IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001; 37 (Suppl 1): S182-238.
12. Wanner C. Importance of hyperlipidaemia and therapy in renal patients. Nephrol Dial Transplant 2000; 15 (Suppl 5): S92-6.
13. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
14. National Kidney Foundation. NKF-K/DOQI clinical practice guidelines for vascular access: update 2000. Am J Kidney Dis 2001; 37 (Suppl 1): S137-81.
15. Bianchi G. Hypertension in chronic renal failure and end-stage renal disease patients treated with haemodialysis or peritoneal dialysis. Nephrol Dial Transplant 2000; 15 (Suppl 5): 105-10.
16. V. Clinical algorithms on cardiovascular risk factors in renal patients. Nephrol Dial Transplant 2000; 15 (Suppl 5): S123-54.
17. Amenabar JJ, Garcia Lopez F, Robles NR, Saracho R, Pinilla J, Gentil MA, Castilla J, Gutierrez JA, Martin-Martinez E, Alonso R, Bernabeu R, Lorenzo V, Vega N, Escallada R, Sierra T, Cleries M, Vela E, Tallon S, Cancho B, Vazquez C, Sanchez-Casajus A, Torralbo A, Ripoll J, Asin JL, Magaz A, Garcia MJ, Zurriaga O. Dialysis and transplantation report of the Spanish Nephrology Society and Autonomous Registries for the year 2000. Nefrologia 2002; 22: 310-7.
18. Perez Garcia R. Spanish survey on anaemia management. Nefrologia 2003; 23: 300-11.
19. Valderrábano F, Hörl WH, Jacobs C, Macdougall IC, Parrondo I, Manhaeve D, Milisen K. Patients and methods. Nephrol Dial Transplant 2000; 15 (Suppl 4): S2-7.
20. Portolés J, López JM, Aljama P. Morbidity, mortality and anemia in HD patients (MAR project). Nefrologia 2002; 22 (Suppl 6): S54.
21. U.S. Renal Data System. USRDS 2003 Annual Data Report. Am J Kidney Dis 2003; 42 (Suppl 5): 1-230.
22. Naya MT, Garrido G, Cuende N, Cañon J Miranda B. Donación y transplante renal en España. Nefrologia 2003; 23: 399-414.
23. Valderrabano F, Horl WH, Macdougall IC, Rossert J, Rutkowski B, Wauters JP. Pre-dialysis survey on anaemia management. Nephrol Dial Transplant 2003; 18 (Suppl 1): S89-100.
24. Portolés J, López J, Aljama P. Morbidity, mortality and anemia in progressive CKD (predialysis MAR 2 project). Nefrologia 2002; 22 (Suppl 6): S34.
25. Perez-Garcia R, Rodriguez-Benitez P, Villaverde MT, Valderrabano F. Is the index of response to erythropoietin (IRE) a good marker of adequate dialysis? Nefrologia 2001; 21: 606-7.
26. Locatelli F, Bommer J, London GM, Martín-Malo A, Wanner C, Yaqoob M, Zoccali C. CV disease determinants in CRF clinical approach and treatment. Nephrol Dial Transplant 2001; 16: 459-68.
27. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected HD patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 2000; 11 (Suppl 2): S335-42.
28. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-90.